Adverse systemic reaction to benznidazole

AUTOR(ES)

Coronel, María Verónica Pacheco, Frutos, Laura Oriente, Muñoz, Eva Calabuig, Valle, Diana Kury, Rojas, Dolores Hernández Fernández de

FONTE

Rev. Soc. Bras. Med. Trop.

DATA DE PUBLICAÇÃO

2017-02

RESUMO

Abstract Benznidazole, drug of choice for Chagas disease (CD), has been associated with a high incidence of adverse reactions that can become serious, necessitating discontinuation of the drug. We describe the case of a Bolivian patient living in Spain for 9 years, who, following treatment with benznidazole for CD in indeterminate chronic phase, presented with fever, skin lesions, digestive symptoms, general malaise, and laboratory abnormalities. After the discontinuation of benznidazole and, the intake of antihistamines and systemic corticosteroids, the patient presented a complete resolution of the symptoms. Optimization of dose strategies and development of more effective, and better-tolerated drugs is advisable.

Documentos Relacionados

• Adverse reaction reports may be vulnerable to manipulation
• Adverse drug reaction reporting controversy
• Adverse reaction monitoring using cohort identification.
• Adverse reaction monitoring using cohort identification.
• ADVERSE REACTION TO ANESTHESIA IN A M.8993T>C CARRIER WITH LEIGH SYNDROME